SPECIFICATIONS

PURITY: ≥ 99.20%
LOT: 24-PP0114
METHOD: HPLC + MS
STORAGE: -20°C
EXP: 04.2028

07 / Peptide Support / PT1-10

PT-141 (Bremelanotide)

Melanocortin receptor agonist

Cyclic heptapeptide. Non-selective melanocortin receptor agonist. 10 mg lyophilized vial.

DOSE

10 MG LYO

QUANTITY

1

BUNDLE & SAVE

$196.00

COA

SHIPS

FRI · 2-5 BIZ DAYS

PAY WITH

USDC · SOLANA

VIEW RESEARCH ↓RESEARCH USE ONLY · NOT FOR HUMAN CONSUMPTION

REFERENCE

RESEARCH

COMPOUND DATA AND PEER-REVIEWED CITATIONS FOR PT-141 (BREMELANOTIDE). FOR RESEARCH USE ONLY.

COMPOUND INFORMATION · TECHNICAL SPECIFICATIONS

MOLECULAR PROFILE

WHAT IS PT-141 (BREMELANOTIDE)?

TYPE: Research compound
CAS: 189691-06-3
MOL. WEIGHT: 1025.2 g/mol
FORMULA: C50H68N14O10
DOSE: 10 MG LYO

SYNONYMS

Bremelanotide189691-06-3Bremelanotida6Y24O4F92SPT-141 FREE BASEPT 141

PUBCHEM DATABASE →

STORAGE REQUIREMENTS

STABILITY INFORMATION

Protect from lightAvoid repeated freeze-thawReconstitute with bacteriostatic water

LYOPHILIZED (POWDER)

-20°C · up to 2 years

RECONSTITUTED

2-8°C · up to 30 days

SOURCES & REFERENCES · PEER-REVIEWED RESEARCH · 8 CITATIONS FOR PT-141 (BREMELANOTIDE)

CURRENT OPINION IN INVESTIGATIONAL DRUGS (LONDON, ENGLAND : 2000)

PT-141 Palatin.

2004 · PMID 15134289

Hedlund P

VIEW SOURCE →

PUBMED

Bremelanotide.

2006 · PMID 31369224

VIEW SOURCE →

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES

PT-141: a melanocortin agonist for the treatment of sexual dysfunction.

IMPORTANT RESEARCH NOTICE

NOT FOR HUMAN CONSUMPTION. THIS PRODUCT IS SOLD EXCLUSIVELY FOR RESEARCH AND EDUCATIONAL PURPOSES. IT IS NOT INTENDED TO DIAGNOSE, TREAT, CURE, OR PREVENT ANY DISEASE.

ALL CITATIONS ON THIS PAGE ARE SOURCED FROM PUBMED AND PUBCHEM PUBLIC DATABASES. THEY ARE PROVIDED FOR EDUCATIONAL REFERENCE ONLY AND SHOULD NOT BE INTERPRETED AS MEDICAL ADVICE OR PRODUCT CLAIMS.

BY PURCHASING THIS PRODUCT, YOU CONFIRM THAT YOU ARE A QUALIFIED RESEARCHER AND WILL USE IT IN ACCORDANCE WITH ALL APPLICABLE LAWS.

2003 · PMID 12851303

Molinoff PB, Shadiack AM et al.

VIEW SOURCE →

EXPERT OPINION ON PHARMACOTHERAPY

Intravenous peptides and amino acids for erectile dysfunction: a narrative review of current applications and future directions.

2025 · PMID 40069591

Ila V, Pozzi E et al.

VIEW SOURCE →

PEPTIDES

Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.

2006 · PMID 16412534

Hadley ME, Dorr RT

VIEW SOURCE →

CURRENT TOPICS IN MEDICINAL CHEMISTRY

Melanocortins in the treatment of male and female sexual dysfunction.

2007 · PMID 17584134

Shadiack AM, Sharma SD et al.

VIEW SOURCE →

UROLOGY

Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response.

2005 · PMID 15833522

Diamond LE, Earle DC et al.

VIEW SOURCE →

INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH

Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra.

2004 · PMID 14999221

Rosen RC, Diamond LE et al.

VIEW SOURCE →